Immune cells that have been genetically engineered using CRISPR technology will be tested for a first time as a potential treatment of metastatic gastrointestinal cancer in a clinical trial. The Phase 1/2 trial (NCT04426669) is enrolling up to 20 eligible patients at the University of Minnesota’s Masonic Cancer Center. Contact information for this single-site study can be found here. Some types of immune cells — most notably T-cells — are able to kill cancer cells. However, cancers…
You must be logged in to read/download the full post.
The post Clinical Trial to Test CRISPR-modified T-cells in Treating Advanced Cancers appeared first on BioNewsFeeds.